EPCAM and neoplasm: specifically linked high CD133 expression to reduced post-TACE OS, tumor multiplicity, vascular invasion, and cirrhosis, whereas EpCAM overexpression—while associated with age, tumor burden, and viral status—showed no OS correlation (128).